Almost every hospital and health system laboratory sends work out. Esoteric testing, molecular and genetic assays, specialized microbiology and low-volume chemistry all go to a reference laboratory rather than being brought in house, and for good reason. The economics of low-volume specialized testing rarely support local capability, and the reference laboratory carries the validation burden.
The agreement governing that relationship has unusually broad operational reach. It determines when results come back and therefore how quickly clinicians can act. It sets prices for a test menu that will change repeatedly over a multi-year term. It allocates specimen handling responsibility and defines when a specimen may be rejected. It governs the interface that delivers results into the laboratory information system and the electronic record. It determines whether the health system bills the payer or receives a client bill from the laboratory.
Most of those terms are written once and then managed informally. Turnaround performance is discussed anecdotally when a clinician complains. Price changes arrive as updated fee schedules that nobody reconciles against the agreement. Interface outages are handled as incidents rather than as service level events. The result is a relationship that works adequately most of the time and has no evidence base when it does not.
Where reference laboratory agreements underperform
Five recurring gaps, each of which converts a service commitment into an informal expectation.
- Turnaround measured from an undefined point, the commitment runs from receipt without saying receipt where, so transport time and accessioning delays fall outside the measured window.
- No performance reporting duty, the agreement states turnaround targets and requires no reporting against them, so the health system has no data to raise a service issue with.
- Test menu changes without notice, tests are added, retired or reassigned to a different methodology, and the first indication is a rejected order or an unexpected price.
- Interface treated as a project, result delivery uptime, format stability and change notification are not service levels, so an interface change breaks orders without warning.
- Billing arrangement ambiguity, client bill and payer bill arrangements are mixed across the menu without a clear mapping, which creates both compliance and revenue cycle exposure.
These gaps are all contract data problems. Turnaround targets, menu versions, interface commitments and billing designations are parameters that belong in systems, monitored on a cadence, in the same way GPO and device contract terms need to be held as data rather than filed as documents.
Write turnaround as time from a specific, evidenced event to a specific deliverable, for example from specimen accession at the reference laboratory to result availability in the interface, stated separately per test or test family. Then require monthly reporting of actual performance against the commitment, with the measurement definition stated. Targets without a defined start point and without reporting cannot be managed, and they are the single most common weakness in these agreements.
Five obligation families to specify and track
Each family carries a cadence and an owner, and each is testable against evidence the agreement should require.
- Turnaround commitments and reporting. Per test or family, measured from a named event, with monthly performance reporting and a defined process where targets are missed repeatedly.
- Test menu and pricing version control. Advance notice of additions, retirements and methodology changes, with each menu and fee schedule version captured with its effective date.
- Specimen handling and rejection criteria. Collection, container, volume, stability and transport requirements, plus the criteria for rejection and the duty to notify promptly when a specimen is rejected.
- Result delivery and interface service levels. Interface availability, result format stability, advance notice of interface changes, and a defined route for reporting and resolving delivery failures.
- Quality and regulatory duties. Maintenance of accreditation and licensure, proficiency testing participation, and notification of adverse survey findings or sanctions affecting the tests you send.
A five-step roadmap for managing send-out testing agreements
Step 1, Reconcile the live test menu against the agreement
Start by comparing what you actually send out against the menu and fee schedule attached to the agreement. Divergence is normal and it is where unrecognized pricing and compliance exposure sits, particularly for tests added informally over time.
Step 2, Define turnaround per test family with a named start event
Rather than a single global target, set commitments by test family and state the measurement definition. Then require the laboratory to report performance monthly using that definition, so both parties are looking at the same number.
Step 3, Version the menu and fee schedule
Capture each menu and fee schedule with an effective date and retain superseded versions. Price reconciliation, revenue cycle mapping and any dispute about what was charged all depend on knowing which version applied when.
Step 4, Make the interface a service level
State availability, format stability, change notice periods and a failure escalation route. An interface that changes without notice creates order failures and result delays that are invisible in turnaround statistics measured at the laboratory.
Step 5, Register the recurring duties with owners
Performance reports, menu change notices, accreditation attestations, proficiency testing confirmations and price schedule updates all become dated obligations with owners, so a missed submission is an exception rather than a discovery.
See laboratory service commitments monitored
Turnaround targets, menu versions, interface service levels and accreditation duties tracked with owners and dates.
Why turnaround data changes the conversation
Laboratory service disputes are usually conducted in anecdotes. A clinician reports that molecular results are taking too long, the laboratory director raises it with the reference laboratory, and the response is that performance is within target. Neither party can move the discussion forward because they are measuring different intervals: the health system experiences time from collection to result in the electronic record, and the reference laboratory reports time from accession to result release. Both numbers are accurate and they differ by transport and accessioning time that nobody owns. Fixing this requires only that the agreement define the measured interval and require reporting against it, and that the health system track its own internal legs separately. Once both are visible, the conversation becomes specific: transport frequency, courier routing, accessioning staffing or laboratory processing, each with a different owner and a different fix. This is the same reason obligation management for healthcare concentrates on measurable commitments rather than on general service language.
Reference laboratory obligation register pattern
The table shows how the agreement terms convert into monitorable entries with evidence.
| Obligation | Cadence or trigger | Owner | Evidence |
|---|---|---|---|
| Turnaround performance report | Monthly | Reference laboratory | Report against stated definition |
| Test menu change notice | Before effective date | Reference laboratory | Notice with effective date |
| Fee schedule version update | On change | Health system contracting | Versioned schedule on file |
| Accreditation attestation | Annual | Reference laboratory | Current certificate and attestation |
| Interface change notice | Before deployment | Reference laboratory | Notice and test confirmation |
A reference laboratory agreement reaches further into clinical operations than most vendor contracts, and it is usually managed with less rigor. The improvements are specific rather than sweeping: define turnaround from a named event and require monthly reporting against that definition, version the test menu and fee schedule with effective dates, write specimen handling and rejection criteria explicitly, treat the result interface as a service level with change notice, and register the recurring reporting and attestation duties with owners. That turns a relationship managed by escalation into one managed by evidence, which is better for the laboratory as well as for the health system.
For related guidance, see Value-based care contract administration, simplified, Business associate agreement obligations at a glance and Delegated entity oversight agreement obligations.
